Karyopharm Therapeutics Inc. (KPTI) financial statements and ratios from SEC XBRL: revenue $146.07M (TTM), net margin -134.2%, revenue growth -11.9% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $146.07M |
| Net Margin | -134.2% |
| Revenue Growth (YoY) | -11.9% |
| EPS Growth (YoY) | -46.3% |
| Price / Sales | 0.30 |
| FCF Yield | -272.0% |
| Altman Z-Score | -23.96 (distress) |
| Sector P/E (Healthcare) | 21.7 |
KPTI overview · KPTI earnings · KPTI KPIs · KPTI investor relations · KPTI ownership · KPTI peers · KPTI filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.